Abiogen Pharma: traditionally present in the “bone metabolism” market
Abiogen Pharma is traditionally present in the “Bone Metabolism” market thanks to the marketing of drugs, born and developed in its Research Centre and now distributed worldwide.
This makes Abiogen Pharma an Italian excellence in this field and it is an important reference point in the national scientific landscape, thanks to its recognized leadership among different specialists.
Abiogen Pharma commercializes therapies destined both for the treatment of more well-known pathologies such as osteoporosis, bone metastases, and osteolysis deriving from multiple myeloma, and for the treatment of rare pathologies such as the Paget syndrome, osteogenesis imperfecta, and algodystrophy, also known as Complex Regional Pain Syndrome (CPRS).
Osteoporosis: the most widespread pathology among bone diseases
Osteoporosis in particular, given its social relevance, is the most widespread pathology among bone diseases, especially owing to fragility fractures, which represent the most relevant clinical form. Even though osteoporotic fractures statistically affect above all post-menopausal women, there is now great awareness of the fact that fractures due to bone fragility are now an important problem also for men.
Algodystrophy or complex regional pain syndrome
Algodystrophy is a rare disease that manifests itself with pain often located in the limbs and resistant to common painkillers. In some cases, but not always, the onset is due to an injury or traumatic event, but the severity of the pain and the trend of the illness are out of proportion to the inciting event. The pain is normally associated with edema and a radiological test may highlight a localized osteoporosis that usually regresses with the regression of the illness. The disease is also known as Complex Regional Pain Syndrome (CRPS) of type 1 and 2.
Osteogenesis imperfecta is a group of hereditary disorders whose hallmarks are bone fragility and skeletal deformity. Other anomalies of the extraskeletal tissues, affecting teeth, skin, and ligaments, may add to these characteristics. The severity of osteogenesis imperfecta ranges from very mild to severe forms according to the bone and skeletal condition as well as to the other extra-skeletal manifestations.